Experimental Antitumor Activity of Platinum Coordination Complexes

  • W. C. Rose
  • W. T. Bradner
Part of the Developments in Oncology book series (DION, volume 17)


The search for a “second-generation” Pt compound to supersede cisplatin has been conducted in many laboratories (1–13). For the past six years, the efforts at Bristol-Myers have been focused on finding analogs with improved antitumor activities and reduced toxicities relative to cisplatin as judged by their effects in animal models (1, 10, 11). The present discussion will be limited to a review of antitumor test results obtained with those Pt compounds now undergoing clinical evaluation, and a few other analogs of potential interest.


Antitumor Activity L1210 Leukemia Normal Bone Marrow Cell Primary Screen Test Improve Antitumor Activity 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Bradner WT, Rose WC, Huftalen JB. 1980. Antitumor activity of platinum analogs. In Cisplatin: Current Status and New Developments (Prestayko AW, Croke ST, and Carter SK, eds.), Academic Press, Inc., New York, pp. 171–182.Google Scholar
  2. 2.
    Burchenal JH, Kalaher K, Dew K, Lokys L, Gale G. 1978. Studies of cross-resistance, synergistic combinations and blocking of activity of platinum derivatives. Biochime 60: 961–965.CrossRefGoogle Scholar
  3. 3.
    Cleare MJ, Hydes PC, Malerbi BW, Watkins DM. 1978. Anti-tumour platinum complexes: relationships between chemical properties and activity. Biochimie 60:835–850.CrossRefGoogle Scholar
  4. 4.
    Connors TA, Cleare MJ, Harrap KR. 1979. Structure-activity relationships of the antitumor platinum coordination complexes. Cancer Treat. 63:1499–1502.Google Scholar
  5. 5.
    Craciunescu DG, Doadrio A, Furlani A, Scarcia V. 1982. Structure-antitumor activity relationships for new platinum complexes. Chem.-Biol. Interactions 42:153–164.CrossRefGoogle Scholar
  6. 6.
    Hall LM, Speer RJ, Ridgway HJ, Norton SJ. 1979. Unsymmetrical C-substituted ethylenediamine platinum coordination complexes: synthesis and activity against mouse leukemia L1210. J. Inorg. Biochem. 11:139–149.PubMedCrossRefGoogle Scholar
  7. 7.
    Kidani Y, Okamoto K, Noji M, Tashiro T. 1978. Antitumor activity of platinum (II) complexes of 1-amino-2-amino-methylcyclohexane isomers. Gann 69:863–864.PubMedGoogle Scholar
  8. 8.
    Meishen SJ, Gale GR, Lake LM, Frangakis CJ, Rosenblum MG, Walker Jr., EM, Atkins LM, Smith AB. 1976. Antileukemic properties of organoplatinum complexes. J. Natl. Cancer Inst. 57:841–845.Google Scholar
  9. 9.
    Pera Jr., MF, Sessford D, Roberts JJ. 1982. Toxicity of cisplatin and hydroxymalonatodiammine platinum (II) towards mouse bone marrow and B16 melanoma in relation to DNA binding in vivo. Biochem. Pharmacol. 31:2273–2278.PubMedCrossRefGoogle Scholar
  10. 10.
    Prestayko AW, Bradner WT, Huftalen JB, Rose WC, Schurig JE, Clear MJ, Hydes PC, Crooke ST. 1979. Antileukemic (L1210) activity and toxicity of cis-dichlorodiammineplatinum (II) analogs. Cancer Treat. Rep 63:1503–1508.PubMedGoogle Scholar
  11. 11.
    Rose WC, Schurig JE, Huftalen JB, Bradner WT. 1982. Antitumor activity and toxicity of cisplatin analogs. Cancer Treat. Rep. 66:135–146.PubMedGoogle Scholar
  12. 12.
    Sheperd R, Kusnierczyk H, Jones M, Harrap KR. 1980. Critera for the selection of second-generation platinum compounds. Br. J. Cancer 42:668–676.CrossRefGoogle Scholar
  13. 13.
    Wolpert-DeFillippes MK. 1980. Antitumor activity of cisplatin analogs.In Cisplatin: Current Status and New Developments (Prestayko AW, Crooke ST and Carter SK, eds.), Academic Press, Inc., New York, pp 183–191.Google Scholar

Copyright information

© Martinus Nijhoff Publishing, Boston 1984

Authors and Affiliations

  • W. C. Rose
  • W. T. Bradner

There are no affiliations available

Personalised recommendations